X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://endpts.com/kymera-doubles-down-on-protein-degraders-for-immunology-chasing-dupixent-and-sotyktu/
https://pharmafile.com/news/bristol-myers-squibbs-sotyktu-recommended-for-nhs-use-for-adult-patients-with-psoriasis/
https://www.barrons.com/articles/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-deucravacitinib-a-once-daily-oral-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis-7a951bf6
https://endpts.com/bristol-myers-debuts-first-psoriasis-drug-ad-on-grammys-leading-chorus-of-pharma-brands/
https://www.fiercepharma.com/pharma/bms-holds-high-sotyktu-hopes-isnt-worried-about-otelza
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.fiercebiotech.com/biotech/nimbus-cloud-9-psoriasis-data-support-taking-rival-bristol-myers-sotyktu-phase-3
https://www.biospace.com/article/releases/health-canada-has-approved-pr-sotyktu-and-8482-deucravacitinib-tablets-an-oral-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis/
https://www.fool.com/investing/2022/09/22/why-bristol-myers-squibb-stock-bounced-higher-toda/
https://www.biopharmadive.com/news/bristol-myers-tyk2-fda-approval-sotyktu-psoriasis/631577/
https://www.fiercebiotech.com/biotech/bms-sets-sights-phase-3-lupus-trial-tyk2-inhibitor-year-after-positive-readout
https://endpts.com/bristol-myers-builds-the-case-for-psoriasis-hopeful-as-it-waits-in-regulatory-limbo/
https://www.fiercebiotech.com/biotech/bms-hints-its-tyk2-inhibitor-could-take-form-lupus-it-looks-widen-meds-scope
https://www.fiercepharma.com/pharma/bristol-s-next-gen-autoimmune-med-not-just-another-jak-drug-exec-says
https://www.biospace.com/article/oral-drug-candidate-for-moderate-to-severe-genital-psoriasis-delivers-positive-phase-iii-results/
https://www.pmlive.com/pharma_news/bms_new_jak_inhibitor_enters_regulatory_pathways_1384682
https://www.fiercepharma.com/pharma/bristol-myers-squibb-enters-fda-review-high-stakes-autoimmune-drug-amid-jak-classwide-safety
https://endpts.com/amid-jak-debacle-bristol-myers-settles-in-for-fdas-long-review-of-potential-first-tyk2-drug/
https://www.fiercepharma.com/pharma/amgen-s-otezla-repatha-and-biosimilars-put-notice-challenging-years-ahead
https://www.fiercebiotech.com/biotech/bristol-myers-deucravacitinib-flunks-midphase-ibd-trial-raising-questions-about-potential
https://news.bms.com/news/details/2021/Bristol-Myers-Squibb-Provides-Update-on-Phase-2-Study-of-Deucravacitinib-in-Patients-With-Moderate-to-Severe-Ulcerative-Colitis/default.aspx
Market Place
Share 
